IL-21 as a therapeutic target in inflammatory disorders

Expert Opinion on Therapeutic Targets

Volumn 18, Issue 11, 2014, Pages 1329-1338

  Di Fusco, Davide ^a   Izzo, Roberta ^a   Figliuzzi, Michele M ^a   Pallone, Francesco ^a   Monteleone, Giovanni ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Crohn's disease; Diabetes; IL 21 receptor; Psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus; Ulcerative colitis

Indexed keywords

INTERLEUKIN 21; ANTIINFLAMMATORY AGENT; INTERLEUKIN DERIVATIVE;

ATOPIC DERMATITIS; BIOLOGICAL ACTIVITY; CROHN DISEASE; CYTOTOXICITY; DISEASE COURSE; GRAFT VERSUS HOST REACTION; HOST; HUMAN; IMMUNE MEDIATED INJURY; IMMUNE RESPONSE; IMMUNE SYSTEM; INFLAMMATORY DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; NEOPLASM; NONHUMAN; OBESITY; PATHOGENICITY; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; TISSUE INJURY; ULCERATIVE COLITIS; ANIMAL; ANTAGONISTS AND INHIBITORS; GENETICS; INFLAMMATION; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; T LYMPHOCYTE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DISEASE PROGRESSION; HUMANS; INFLAMMATION; INTERLEUKINS; MOLECULAR TARGETED THERAPY; T-LYMPHOCYTES;

EID: 84911498513     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.945426     Document Type: Review

References (100)

1. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations. Annu Rev Immunol 2010;28:445-89
2. Tayal V, Kalra BS. Cytokines and anticytokines as therapeutics - an update. Eur J Pharmacol 2008;579:1-12
3. Spolski R, Leonard WJ. Interleukin-21: a double-edged sword with therapeutic potential. Nat Rev Drug Discov 2014;13:379-95
4. Parrish-Novak J, Dillon SR, Nelson A, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000;408:57-63
5. Korn T, Bettelli E, Gao W, et al. IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells. Nature 2007;448:484-7
6. Zhou L, Ivanov II, Spolski R, et al. IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007;8:967-74
7. Wurster AL, Rodgers VL, Satoskar AR, et al. Interleukin 21 is a T helper (Th) cell 2 cytokine that specifically inhibits the differentiation of naive Th cells into interferon gamma-producing Th1 cells. J Exp Med 2002;196:969-77
8. Sarra M, Monteleone I, Stolfi C, et al. Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases. Inflamm Bowel Dis 2010;16:1332-9
9. Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348-57
10. Mehta DS, Wurster AL, Weinmann AS, et al. NFATc2 and T-bet contribute to T-helper-cell-subset-specific regulation of IL-21 expression. Proc Natl Acad Sci USA 2005;102:2016-21
11. Chen G, Hardy K, Bunting K, et al. Regulation of the IL-21 gene by the NF-kB transcription factor c-Rel. J Immunol 2010;185:2350-9
12. Monteleone G, Pallone F, MacDonald TT. Interleukin-21: a critical regulator of the balance between effector and regulatory T-cell responses. Trends Immunol 2008;29:290-4
13. Liu SM, King C. IL-21-producing Th cells in immunity and autoimmunity. J Immunol 2013;191:3501-6
14. Kwon H, Thierry-Mieg D, Thierry-Mieg J, et al. Analysis of interleukin-21-induced Prdm1 gene regulation reveals functional cooperation of STAT3 and IRF4 transcription factors. Immunity 2009;31:941-52
15. Huber M, Brustle A, Reinhard K, et al. IRF4 is essential for IL-21-mediated induction, amplification, and stabilization of the Th17 phenotype. Proc Natl Acad Sci USA 2008;105:20846-51
16. Ho IC, Lo D, Glimcher LH. C-maf promotes T helper cell type 2 (Th2) and attenuates Th1 differentiation by both interleukin 4-dependent and - independent mechanisms. J Exp Med 1998;188:1859-66
17. Bauquet AT, Jin H, Paterson AM, et al. The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells. Nat Immunol 2009;10:167-75
18. Williams LD, Amatya N, Bansal A, et al. Immune activation is associated with CD8 T-cell IL-21 production in HIV-1-infected individuals. J Virol 2014. [Epub ahead of print]
19. Quandt D, Rothe K, Scholz R, et al. Peripheral CD4CD8 double positive T cells with a distinct helper cytokine profile are increased in rheumatoid arthritis. PLoS One 2014;9(3):1
20. Parrish-Novak J, Foster DC, Holly RD, et al. Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J Leukoc Biol 2002;72:856-63
21. Habib T, Senadheera S, Weinberg K, et al. The common gamma chain (gamma c) is a required signaling component of the IL-21 receptor and supports IL-21-induced cell proliferation via JAK3. Biochemistry 2002;41:8725-31
22. Zeng R, Spolski R, Casas E, et al. The molecular basis of IL-21-mediated proliferation. Blood 2007;109:4135-42
23. Fuqua CF, Akomeah R, Price JO, et al. Involvement of ERK-1/2 in IL-21-induced cytokine production in leukemia cells and human monocytes. Cytokine 2008;44:101-7
24. Vallières F, Girard D. IL-21 enhances phagocytosis in mononuclear phagocyte cells: identification of spleen tyrosine kinase as a novel molecular target of IL-21. J Immunol 2013;190:2904-12
25. Spolski R, Leonard WJ. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol 2008;26:57-79
26. Spolski R, Leonard WJ. The Yin and Yang of interleukin-21 in allergy, autoimmunity and cancer. Curr Opin Immunol 2008;20:295-301
27. Fina D, Fantini MC, Pallone F, et al. Role of interleukin-21 in inflammation and allergy. Inflamm Allergy Drug Targets 2007;6:63-8
28. Fantini MC, Rizzo A, Fina D, et al. IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells. Eur J Immunol 2007;37:3155-63
29. Peluso I, Fantini MC, Fina D, et al. IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J Immunol 2007;178:732-9
30. Vogelzang A, McGuire HM, Liu SM, et al. IL-21 contributes to fatal inflammatory disease in the absence of Foxp3+ T regulatory cells. J Immunol 2014;192:1404-14
31. Knights D, Lassen KG, Xavier RJ. Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome. Gut 2013;62:1505-10
32. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012;491:119-24
33. Macdonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science 2005;307:1920-5
34. Monteleone G, Monteleone I, Fina D, et al. Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology 2005;128:687-94
35. Festen EA, Goyette P, Scott R, et al. Genetic variants in the region harbouring IL2/IL21 associated with ulcerative colitis. Gut 2009;58:799-804
36. Caruso R, Fina D, Peluso I, et al. IL-21 is highly produced in Helicobacter pylori-infected gastric mucosa and promotes gelatinases synthesis. J Immunol 2007;178:5957-65
37. Bodd M, Ráki M, Tollefsen S, et al. HLA-DQ2-restricted gluten-reactive T cells produce IL-21 but not IL-17 or IL-22. Mucosal Immunol 2010;3:594-601
38. Fina D, Sarra M, Caruso R, et al. Interleukin 21 contributes to the mucosal T helper cell type 1 response in coeliac disease. Gut 2008;57:887-92
39. Fina D, Sarra M, Fantini MC, et al. Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology 2008;134:1038-48
40. Cupi ML, Sarra M, Marafini I, et al. Plasma cells in the mucosa of patients with inflammatory bowel disease produce granzyme B and possess cytotoxic activities. J Immunol 2014;192(12):6083-91
41. Monteleone G, Caruso R, Fina D, et al. Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21. Gut 2006;55:1774-80
42. Caruso R, Fina D, Peluso I, et al. A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells. Gastroenterology 2007;132:166-75
43. Kwon JH, Keates S, Bassani L, et al. Colonic epithelial cells are a major site of macrophage inflammatory protein 3alpha (MIP-3alpha) production in normal colon and inflammatory bowel disease. Gut 2002;51:818-26
44. Stolfi C, Rizzo A, Franzè E, et al. Involvement of interleukin-21 in the regulation of colitis-associated colon cancer. J Exp Med 2011;208:2279-90
45. Salzer E, Kansu A, Sic H, et al. Early-onset inflammatory bowel disease and common variable immunodeficiency-like disease caused by IL-21 deficiency. J Allergy Clin Immunol 2014;133(6):1651-9
46. Yeste A, Mascanfroni ID, Nadeau M, et al. IL-21 induces IL-22 production in CD4+ T cells. Nat Commun 2014;5:3753
47. Caruso R, Botti E, Sarra M. Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med 2009;15:1013-15
48. Perera GK, Di Meglio P, Nestle FO. Psoriasis. Annu Rev Pathol 2012;7:385-422
49. Caruso R, Costanzo A, Monteleone G. Pathogenic role of interleukin-21 in psoriasis. Cell Cycle 2009;8:3629-30
50. Sarra M, Caruso R, Cupi ML, et al. IL-21 promotes skin recruitment of CD4 (+) cells and drives IFN-gamma-dependent epidermal hyperplasia. J Immunol 2011;186:5435-42
51. Gedebjerg A, Johansen C, Kragballe K, et al. IL-20, IL-21 and p40: potential biomarkers of treatment response for ustekinumab. Acta Derm Venereol 2013;93:150-5
52. Jin H, Oyoshi MK, Le Y, et al. IL-21R is essential for epicutaneous sensitization and allergic skin inflammation in humans and mice. J Clin Invest 2009;119:47-60
53. Maiti AK, Kim-Howard X, Viswanathan P, et al. Confirmation of an association between rs6822844 at the Il2-Il21 region and multiple autoimmune diseases: evidence of a general susceptibility locus. Arthritis Rheum 2010;62:323-9
54. Chen XL, Bobbala D, Rodriguez GM, et al. Induction of autoimmune diabetes in non-obese diabetic mice requires interleukin-21-dependent activation of autoreactive CD8+ T cells. Clin Exp Immunol 2013;173:184-94
55. McGuire HM, Walters S, Vogelzang A, et al. Interleukin-21 is critically required in autoimmune and allogeneic responses to islet tissue in murine models. Diabetes 2011;60:867-75
56. Sutherland AP, Joller N, Michaud M, et al. IL-21 promotes CD8+ CTL activity via the transcription factor T-bet. J Immunol 2013;190:3977-84
57. Fabrizi M, Marchetti V, Mavilio M, et al. IL-21 is a major negative regulator of IRF4-dependent lipolysis affecting Tregs in adipose tissue and systemic insulin sensitivity. Diabetes 2014;63(6):2086-96
58. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376:1094-108
59. Jüngel A, Distler JH, Kurowska-Stolarska M, et al. Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. Arthritis Rheum 2004;50:1468-76
60. Kwok SK, Cho ML, Park MK, et al. Interleukin-21 promotes osteoclastogenesis in humans with rheumatoid arthritis and in mice with collagen-induced arthritis. Arthritis Rheum 2012;64:740-51
61. Rasmussen TK, Andersen T, Hvid M, et al. Increased interleukin 21 (IL-21) and IL-23 are associated with increased disease activity and with radiographic status in patients with early rheumatoid arthritis. J Rheumatol 2010;37:2014-20
62. Sglunda O, Mann HF, Hulejová H, et al. Decrease in serum interleukin 21 levels is associated with disease activity improvement in patients with recent-onset rheumatoid arthritis. Physiol Res 2014. [Epub ahead of print]
63. Carbone G, Wilson A, Diehl SA. Interleukin-6 receptor blockade selectively reduces IL-21 production by CD4 T cells and IgG4 autoantibodies in rheumatoid arthritis. Int J Biol Sci 2013;9:279-88
64. Li J, Shen W, Kong K, et al. Interleukin-21 induces T-cell activation and proinflammatory cytokine secretion in rheumatoid arthritis. J Immunol 2006;64:515-22
65. Young DA, Hegen M, Ma HL. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum 2007;56:1152-63
66. Kouskoff V, Korganow AS, Duchatelle V, et al. Organ-specific disease provoked by systemic autoimmunity. Cell 1996;87:811-22
67. Jang E, Cho SH, Park H, et al. A positive feedback loop of IL-21 signaling provoked by homeostatic CD4+ CD25- T cell expansion is essential for the development of arthritis in autoimmune K/BxN mice. J Immunol 2009;182:4649-56
68. Block KE, Huang H. The cellular source and target of IL-21 in K/BxN autoimmune arthritis. J Immunol 2013;191:2948-55
69. Marijnissen RJ, Roeleveld DM, Young D, et al. Interleukin-21 receptor deficiency increases the initial toll-like receptor 2 response but protects against joint pathology by reducing Th1 and Th17 cells during streptococcal cell wall arthritis. Arthritis Rheumatol 2014;66:886-95
70. Sawalha AH, Kaufman KM, Kelly JA, et al. Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus. Ann Rheum Dis 2008;67:458-61
71. Webb R, Merrill JT, Kelly JA, et al. A polymorphism within IL21R confers risk for systemic lupus erythematosus. Arthritis Rheum 2009;60:2402-7
72. Lan Y, Luo B, Wang JL, et al. The association of interleukin-21 polymorphisms with interleukin-21 serum levels and risk of systemic lupus erythematosus. Gene 2014;538:94-8
73. Sarra M, Monteleone G. Interleukin-21: a new mediator of inflammation in systemic lupus erythematosus. J Biomed Biotechnol 2010;2010:294582
74. Lee J, Shin EK, Lee SY, et al. Estrogen upregulates IL-21 production by CD4+ T lymphocytes in patients with systemic lupus erythematosus. Immunology 2014. [Epub ahead of print]
75. Izui S, Ibnou-Zekri N, Fossati-Jimack L, et al. Lessons from BXSB and related mouse models. Int Rev Immunol 2000;19:447-72
76. Bubier JA, Bennett SM, Sproule TJ, et al. Treatment of BXSB-Yaa mice with IL-21R-Fc fusion protein minimally attenuates systemic lupus erythematosus. Ann N Y Acad Sci 2007;1110:590-601
77. Bubier JA, Sproule TJ, Foreman O, et al. A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice. Proc Natl Acad Sci USA 2009;106:1518-23
78. McPhee CG, Bubier JA, Sproule TJ, et al. IL-21 is a double-edged sword in the systemic lupus erythematosus-like disease of BXSB.Yaa mice. J Immunol 2013;191:4581-8
79. Herber D, Brown TP, Liang S, et al. IL-21 has a pathogenic role in a lupus prone mouse model and its blockade with IL-21R.Fc reduces disease progression. J Immunol 2007;178:3822-30
80. Rankin AL, Guay H, Herber D, et al. IL-21 receptor is required for the systemic accumulation of activated B and T lymphocytes in MRL/MpJ-Fas(lpr/lpr)/J mice. J Immunol 2012;188:1656-67
81. Geri G, Terrier B, Rosenzwajg M, et al. Critical role of IL-21 in modulating TH17 and regulatory T cells in Behc¸et disease. J Allergy Clin Immunol 2011;128:655-64
82. Li D, Cai W, Gu R, et al. Th17 cell plays a role in the pathogenesis of Hashimoto's thyroiditis in patients. Clin Immunol 2013;149:411-20
83. Zhang J, Zeng H, Ren M, et al. Interleukin-21 is associated with disease activity in patients with Graves' disease. Endocrine 2013. [Epub ahead of print]
84. Yi JS, Guidon A, Sparks S, et al. Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis. J Autoimmun 2013. [Epub ahead of print]
85. Xiao F, Zhang HY, Liu YJ, et al. Higher frequency of peripheral blood interleukin 21 positive follicular helper T cells in patients with ankylosing spondylitis. J Rheumatol 2013;40:2029-37
86. Zhang Q, Bai H, Wang W. Increased percentages of T cells producing interleukin-21 in patients with immune thrombocytopenic purpura. Cell Biol Int 2014;38:520-5
87. Li Q, Liu Z, Dang E, et al. Follicular helper T Cells (Tfh) and IL-21 involvement in the pathogenesis of bullous pemphigoid. PLoS One 2013;8:e68145
88. Gong YZ, Nititham J, Taylor K, et al. Differentiation of follicular helper T cells by salivary gland epithelial cells in primary Sj€ogren's syndrome. J Autoimmun 2014;51:57-66
89. McGuire HM, Vogelzang A, Ma CS, et al. A subset of interleukin-21+ chemokine receptor CCR9+ T helper cells target accessory organs of the digestive system in autoimmunity. Immunity 2011;34:602-15
90. Nohra R, Beyeen AD, Guo JP, et al. RGMA and IL21R show association with experimental inflammation and multiple sclerosis. Genes Immun 2010;11:279-93
91. Tzartos JS, Craner MJ, Friese MA, et al. IL-21 and IL-21 receptor expression in lymphocytes and neurons in multiple sclerosis brain. Am J Pathol 2011;178:794-802
92. Liu R, Bai Y, Vollmer TL, et al. IL-21 receptor expression determines the temporal phases of experimental autoimmune encephalomyelitis. Exp Neurol 2008;211:14-24
93. Clarkson BD, Ling C, Shi Y, et al. T cell-derived interleukin (IL)-21 promotes brain injury following stroke in mice. J Exp Med 2014;211:595-604
94. Wu X, Tan Y, Xing Q, et al. IL-21 accelerates xenogeneic graft-versus-host disease correlated with increased B-cell proliferation. Protein Cell 2013;4:863-71
95. Hippen KL, Bucher C, Schirm DK, et al. Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes. Blood 2012;119:619-28
96. Hanash AM, Kappel LW, Yim NL, et al. Abrogation of donor T-cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD from GVL. Blood 2011;118:446-55
97. Meguro A, Ozaki K, Oh I, et al. IL-21 is critical for GVHD in a mouse model. Bone Marrow Transplant 2010;45:723-9
98. Hua F, Comer GM, Stockert L, et al. Anti-IL21 receptor monoclonal antibody (ATR-107): safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. J Clin Pharmacol 2014;54:14-22
99. Yeste A, Mascanfroni ID, Nadeau M, et al. IL-21 induces IL-22 production in CD4+ T cells. Nat Commun 2014;5:3753
100. Silva LC, Ortigosa LC, Benard G. Anti-TNF-alpha agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy 2010;2:817-33